Macrocycles sit between small molecules and biologics: large enough to cover an extended interface, constrained enough to avoid paying full entropic cost, and — under the right conditions — capable of crossing membranes despite exceeding conventional property limits. We design macrocyclic molecules that combine peptide and small-molecule features, scan macrocyclisation positions and linker chemistry, generate conformational ensembles and optimise the permeability-versus-potency trade-off that governs this chemical space.
Computational predictions prioritise hypotheses; they do not independently establish binding, biological activity, therapeutic efficacy, safety or clinical validity. Performance depends on input quality, target class, the structural evidence available and the applicability domain of the selected methods. Scores used for ranking are comparative devices and should not be read as measured quantities. All deliverables are for research use only and are not intended for diagnostic or therapeutic use.
These are the failure modes that produce confident-looking results which do not survive the next experiment. Each one is designed against rather than discovered afterwards.
Illustrative of the shape this work takes. Details are generalised, no client or target is identified, and scope and outcome vary with the system in question.
Note: ICDMO delivers computational (in silico) services. Results prioritise hypotheses for testing; they do not by themselves establish binding, biological activity, efficacy or safety. All deliverables are for research use only and are not intended for diagnostic or therapeutic use. Downstream experimental work is scoped separately and executed through qualified partners.
Our scientific team responds within 24 hours with a detailed technical proposal and pricing tailored to your project.
Contact Us Online Consultation